222 related articles for article (PubMed ID: 2104923)
1. High-dose ifosfamide with mesna uroprotection: a phase I study.
Elias AD; Eder JP; Shea T; Begg CB; Frei E; Antman KH
J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study.
Bernstein ML; Whitehead VM; Devine S; Grier H; Kung F; Krischer J; Dreyer Z; Bell B; Land V; Buchanan GR
Cancer; 1993 Sep; 72(5):1790-4. PubMed ID: 8348510
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
Scheulen ME; Niederle N; Bremer K; Schütte J; Seeber S
Cancer Treat Rev; 1983 Sep; 10 Suppl A():93-101. PubMed ID: 6414700
[TBL] [Abstract][Full Text] [Related]
6. Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.
Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Hunt M; Critchlow J; Schnipper L; Frei E
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S208-13. PubMed ID: 1795009
[TBL] [Abstract][Full Text] [Related]
7. Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
Toma S; Palumbo R; Comandone A; Oliva C; Vincenti M; Bumma C; Rosso R
Ann Oncol; 1995 Feb; 6(2):193-6. PubMed ID: 7540421
[TBL] [Abstract][Full Text] [Related]
8. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
9. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
Stuart-Harris RC; Harper PG; Parsons CA; Kaye SB; Mooney CA; Gowing NF; Wiltshaw E
Cancer Chemother Pharmacol; 1983; 11(2):69-72. PubMed ID: 6414732
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
Elias AD; Antman KH
Cancer Treat Rep; 1986 Jul; 70(7):827-33. PubMed ID: 3087617
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
Palumbo R; Palmeri S; Antimi M; Gatti C; Raffo P; Villani G; Toma S
Ann Oncol; 1997 Nov; 8(11):1159-62. PubMed ID: 9426338
[TBL] [Abstract][Full Text] [Related]
12. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
Elias AD; Wheeler C; Ayash LJ; Schwartz G; Ibrahim J; Mills L; McCauley M; Coleman N; Warren D; Schnipper L; Antman KH; Teicher BA; Frei E
Clin Cancer Res; 1998 Jun; 4(6):1443-9. PubMed ID: 9626461
[TBL] [Abstract][Full Text] [Related]
14. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
[TBL] [Abstract][Full Text] [Related]
16. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Cancer Chemother Pharmacol; 1990; 26 Suppl():S55-8. PubMed ID: 2112054
[TBL] [Abstract][Full Text] [Related]
17. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Palackdharry CS
Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
[TBL] [Abstract][Full Text] [Related]
19. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
Antman KH; Ryan L; Elias A; Sherman D; Grier HE
J Clin Oncol; 1989 Jan; 7(1):126-31. PubMed ID: 2491883
[TBL] [Abstract][Full Text] [Related]
20. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
Sanchiz F; Milla A
Cancer Chemother Pharmacol; 1990; 26 Suppl():S91-2. PubMed ID: 2112057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
